AbCellera and Vancouver’s Biotech Cluster: From COVID Antibodies to a Long Rebuild

AbCellera’s story is a test of whether a one-off pandemic windfall can be converted into a durable drug company, and in 2026 the evidence is finally starting to come in. Founded in 2012 by Carl Hansen out of the University of British Columbia, the company earned more from one antibody in two years than most Canadian biotechs earn in their lifetimes, then watched that revenue vanish. Its response was to invest in laboratories, a clinical manufacturing plant and a pipeline of its own molecules rather than return the cash. This article traces the windfall, the slump, the 2025-2026 rebuild and the wider Vancouver cluster of which AbCellera is the anchor. It is part of the Canada Company Stories hub.

How did a UBC spin-out become the fastest antibody shop in the pandemic?

AbCellera’s edge was speed in finding antibodies, not making drugs, and the pandemic rewarded exactly that. Carl Hansen, a UBC physics professor, had developed microfluidic devices that could isolate and sequence single antibody-producing cells; AbCellera combined that hardware with machine learning and a large data operation to screen millions of cells in days rather than months.

Before 2020 the company was a contract-discovery business with clients including Pfizer, Novartis and the US Defense Advanced Research Projects Agency, whose pandemic-preparedness funding had paid for part of the platform. When SARS-CoV-2 emerged, AbCellera received a blood sample from an early US patient, screened it and, together with Eli Lilly, took the antibody that became bamlanivimab from discovery to first human dose in roughly 90 days.

The US government bought millions of doses under emergency authorisation. AbCellera’s royalty share turned a company with modest revenue into one booking hundreds of millions of dollars, and in December 2020 it listed on Nasdaq at US$20 a share, raising about US$483 million in one of the largest Canadian tech IPOs of the era. For a few months its market capitalisation exceeded US$15 billion.

What happened when the COVID royalties stopped?

The windfall ended as abruptly as it arrived. Bamlanivimab lost effectiveness against later variants and its emergency authorisation was revoked; a successor antibody, bebtelovimab, followed the same path in late 2022. AbCellera’s revenue fell year after year, reaching US$28.8 million in 2024, while operating expenses did not. The shares, which had traded above US$70, spent most of 2024 and 2025 below US$4.

The 2025 results published on 24 February 2026 show the shape of the business after the slump: revenue of US$75.1 million, lifted by US$46.9 million of licensing and royalty income that included a patent-litigation settlement; research and development spending of US$186.8 million; and a net loss of US$146.4 million, narrower than 2024’s US$162.9 million. Partners had started 104 programmes with downstream rights for AbCellera, and 19 molecules had reached the clinic, but the royalty stream from those programmes is years away.

What distinguishes AbCellera from other post-pandemic busts is what it did with the cash. Instead of a buyback, it spent on a 380,000 square foot campus in Vancouver, a GMP clinical manufacturing facility that opened in 2025, and a team of several hundred scientists. Investors who wanted a capital return were unimpressed; those who wanted a Canadian version of Regeneron were asked to wait.

Why did AbCellera decide to develop its own drugs?

Contract discovery is a fine business but it does not capture most of the value of a successful antibody, and AbCellera concluded by 2023 that it needed its own pipeline. Partner-led programmes give the company milestones and single-digit royalties; wholly owned programmes, if partnered after clinical proof, command upfront payments in the tens of millions and double-digit economics.

The first two internal candidates target well-understood biology with a differentiated format. ABCL635 is an antibody against the neurokinin-3 receptor (NK3R), the same target as Astellas’s oral drug fezolinetant for menopausal vasomotor symptoms, but delivered as a long-acting injection. ABCL575 targets OX40 ligand for atopic dermatitis, a mechanism being pursued by Amgen and Sanofi. In both cases the thesis is that a long-acting antibody can replace a daily pill or a frequent injection.

Alongside these, ABCL386 and ABCL688 are in IND-enabling studies, and the company’s T-cell engager platform has attracted partners. In 2026 AbCellera signed a deal with Jazz Pharmaceuticals for next-generation T-cell engagers in gastrointestinal cancers, with US$84 million of upfront payments and up to US$792 million per programme in milestones, and on 29 July 2026 a collaboration with Vertex on multispecific T-cell engagers for autoimmune disease, with US$28 million upfront. Chief executive Carl Hansen noted that the new collaborations added more than US$100 million of upfront cash.

What did the ABCL635 Phase 2 trial show?

On 10 August 2026 AbCellera reported top-line results from a randomised, double-blind, placebo-controlled Phase 2 trial of ABCL635 in 92 postmenopausal women with an average of about ten moderate or severe hot flashes a day. A single 600 mg subcutaneous dose reduced daily events by 8.8 at week four, compared with 3.5 for placebo, a placebo-adjusted reduction of 5.3 events (83 per cent versus 33 per cent, p<0.001). Severity scores fell 58 per cent versus 12 per cent. Significance was reached from week one and maintained through week four.

There were no serious adverse events and no discontinuations; the most common side effects were headache, fatigue and injection-site reactions. Investigator JoAnn Pinkerton said that, if validated in Phase 3, the drug could offer a more convenient regimen than current options. The company estimates that more than 12 million women in the United States have moderate-to-severe vasomotor symptoms and that more than six million seek treatment.

The commercial logic is straightforward. Fezolinetant (Veozah) and Bayer’s elinzanetant are daily oral NK3R drugs; a once-monthly or less frequent injection with a clean safety profile would compete directly. AbCellera has not yet disclosed Phase 3 timing or whether it will partner the asset, which are the two questions its investors most want answered.

How strong is AbCellera’s balance sheet after the August 2026 raise?

AbCellera entered the ABCL635 readout with more cash than most clinical-stage biotechs and then added to it. At 30 June 2026 it held about US$565 million in cash, equivalents, marketable securities and restricted cash, and counted a further US$110 million of available non-dilutive government funding for total liquidity of more than US$675 million. Second-quarter revenue was only US$4.1 million and the net loss US$55.4 million, so the cash burn is real, but the runway was already several years.

Two days after the Phase 2 data, on 12 August 2026, the company priced an oversubscribed US$200 million public offering of common shares and pre-funded warrants. Raising equity on good news, at a higher price, is the textbook move, and it gives the company the option of taking ABCL635 into Phase 3 without a partner if the terms on offer are poor.

The government money is a distinctive feature. Canada’s Strategic Innovation Fund and the Province of British Columbia announced in 2023 a combined contribution of several hundred million Canadian dollars toward AbCellera’s Vancouver campus and manufacturing plant, and the balance sheet carried US$178.3 million of deferred government contributions at mid-2026. That support reflects a deliberate federal policy after the pandemic to rebuild domestic biomanufacturing, a theme that also appears in Ottawa’s industrial strategy for EV battery plants.

Who else makes up Vancouver’s biotech cluster?

Vancouver’s cluster is anchored by a handful of companies with real scale and a long tail of university spin-outs. Zymeworks, founded in 2003, developed zanidatamab, a HER2-targeting bispecific antibody sold by Jazz Pharmaceuticals as Ziihera. It won US approval for biliary tract cancer in 2024, and the first-line gastroesophageal adenocarcinoma decision due on 25 August 2026 carried a US$250 million milestone. Zymeworks reported Q2 2026 revenue of US$4.6 million, a net loss of US$45 million and US$322.5 million of cash, and is buying Theravance Biopharma for its royalty stream.

Xenon Pharmaceuticals, based in Burnaby with a Boston office, is Canada’s best-funded neuroscience biotech. Its potassium-channel opener azetukalner completed the Phase 3 X-TOLE2 study in focal seizures, and the company planned a US new drug application in the third quarter of 2026. Xenon held US$1.245 billion in cash at 30 June 2026, enough to fund operations into 2029, and is running a second Phase 3 in major depressive disorder with data expected in the first half of 2027.

Stemcell Technologies, founded by Allen Eaves in 1993, is the quiet giant: a privately held maker of cell-culture media and reagents that describes itself as Canada’s largest biotechnology company by employees, with a large manufacturing campus in Burnaby. Around these sit adMare BioInnovations, the national commercialisation organisation headquartered in Vancouver, Aspect Biosystems in bioprinting, and a steady flow of spin-outs from UBC and the BC Cancer Agency.

Why does Vancouver still lag Boston and the Bay Area?

The honest comparison is unflattering in scale but not in quality. Vancouver has perhaps a dozen biotechs with more than US$100 million in cash; Boston has hundreds. Canadian venture funding for life sciences remains a fraction of US levels, and most Canadian biotechs still list on Nasdaq, incorporate US subsidiaries and recruit senior management from the United States, because the capital and the experienced executives are there.

Three structural issues recur. First, the Canadian talent pool for late-stage clinical development and commercial launch is thin, so companies like Xenon and Zymeworks build US offices as they approach approval. Second, the Toronto Stock Exchange has not developed a deep biotech investor base, which is why AbCellera, Zymeworks and Xenon are all Nasdaq-only listings. Third, the Canadian drug-pricing regime, discussed in our article on Apotex and Canada’s generics industry, makes the home market a small and slow launch market, so Canadian biotechs are built from day one to sell in the United States.

Against that, Vancouver has advantages that Boston cannot copy: a lower cost base, a strong immigration pipeline, proximity to Seattle and San Francisco in the same time zone, and public universities that have been producing antibody and cell-therapy talent for forty years. The federal Strategic Innovation Fund money that supported AbCellera’s campus is an explicit attempt to turn those advantages into retained manufacturing jobs rather than exported science.

What are the main risks for AbCellera and its peers?

The central risk for AbCellera is that ABCL635’s Phase 2 result does not survive a larger, longer Phase 3. Menopause drugs face regulators who scrutinise liver safety closely, as fezolinetant’s boxed warning showed, and a 92-patient trial cannot answer those questions. The company must also choose between funding Phase 3 alone and partnering, and the market will read a partnership on poor terms as a lack of confidence.

A second risk is the platform business. Partner-led programmes fell from 44 at the end of 2025 to 35 by mid-2026 as partners pruned pipelines, and quarterly research-fee revenue has shrunk to single-digit millions. If large pharma continues to cut early-stage spending, AbCellera’s discovery revenue will keep falling even as its own pipeline advances.

For the cluster as a whole, the risk is a US biotech downturn. Every major Vancouver company depends on Nasdaq for capital and on US partners for commercialisation, and a Canadian company with a US$1 billion cash pile, like Xenon, is also a tempting acquisition target that could be moved out of the province after a deal.

What can founders and investors learn from AbCellera and Vancouver?

The first lesson is that platforms need products. AbCellera’s discovery engine was genuinely faster than rivals’, but partners captured most of the value, and investors stopped paying for the platform once the pandemic revenue was gone. A biotech that owns no molecules has no path to the valuations of Regeneron or Genmab, both of which also began as platform companies before building their own drugs. The opposite failure, owning molecules but drowning in debt, is the subject of our Bausch Health and Valeant story.

The second is about fundraising discipline. AbCellera raised equity twice at exactly the right moments: at the peak of pandemic enthusiasm in December 2020 and immediately after positive data in August 2026. In between, it did not dilute shareholders at depressed prices despite a falling share price and a large burn. That sequencing was possible only because the 2020 raise was sized generously; the lesson for founders is to raise more than you need when the market is open.

The third lesson is for policymakers and anchor investors. Vancouver’s cluster exists because of forty years of public investment in UBC, the BC Cancer Agency and the Michael Smith laboratories, plus a handful of founders who stayed. Government money attached to physical infrastructure, as with AbCellera’s campus, tends to anchor companies more effectively than tax credits, a pattern that also appears in how Cohere has been supported as a Canadian AI champion. For a comparison with another small country trying to hold on to its science, see the Australia Company Stories hub, where CSL offers a rare example of a domestic biotech that became a global leader without leaving home.

Frequently Asked Questions